Solid Lipid Nanoparticles Carrying Oligonucleotides Inhibit Vascular Endothelial Growth Factor Expression in Rat Glioma Models

Brioschi, Andrea; Calderoni, Sara; Pradotto, Luca; Guido, Marilena; Strada, Alberto; Zenga, Francesco; Benech, Carlo Alberto; Benech, Franco; Serpe, Loredana; Zara, Gian Paolo; Musicanti, Claudia; Ducati, Alessandro; Gasco, Maria Rosa; Mauro, Alessandro

doi:10.1166/jns.2009.007

Cited by 10 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6c) acquired on this region exhibits lack of the P X-ray signal (which should arise from the lipid shell) and a very weak osmium signal in comparison to the strong iron signal. This residual osmium signal could be due to unreacted surfactant molecules used during the microemulsion process (Brioschi et al, 2009), which were dispersed in the solution and randomly deposited on the TEM grid without forming the lipid shell around the iron oxide NPs. Acquired EDX spectra (Fig.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Transmission Electron Microscopy of Lipid Vesicles for Drug Delivery: Comparison between Positive and Negative Staining

Bello¹,

Mattei²,

Mazzoldi³

et al. 2010

Microsc Microanal

View full text Add to dashboard Cite

Lipid-containing nanostructures, in the form of solid lipid nanoparticles or iron oxide nanoparticles (NPs) coated with a lipid shell, were used as case studies for assessing and optimizing staining for transmission electron microscopy structural and compositional characterization. These systems are of paramount importance as drug delivery systems or as bio-compatible contrast agents. In particular, we have treated the systems with a negative (phospshotungstic acid) or with a positive (osmium tetroxide) staining agent. For iron-oxide NPs coated with the lipid shell, negative staining was more efficient with respect to the positive one. Nevertheless, in particular cases the combination of the two staining procedures provided more complete morphological and compositional characterization of the particles.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The unloaded SLNs were prepared by water in oil in water microemulsion technique (Brioschi et al, 2009). A similar microemulsion technique was used to coat with a lipid layer USPIO NPs.…”

Section: Methodsmentioning

confidence: 99%

Transmission Electron Microscopy of Lipid Vesicles for Drug Delivery: Comparison between Positive and Negative Staining

Bello¹,

Mattei²,

Mazzoldi³

et al. 2010

Microsc Microanal

View full text Add to dashboard Cite

show abstract

“…Similar results were obtained in in vivo study in which a pronounced VEGF reduction was obtained in central and peripheral tumor regions of rats treated with SLNs carrying VEGF antisense oligonucleotides, while results were not considerable after free VEGF antisense oligonucleotides treatment (without NPs). Both in vitro and in vivo rat glioma models demonstrated potential in reducing VEGF expression via VEGF antisense oligonucleotides containing SLNs [65].…”

Section: Acquired Immunodeficiency Syndrome (Aids)mentioning

confidence: 99%

Targeted Brain Delivery of Bioactive Molecules Using Nanocarriers

Kr¹,

Gajbhiye²,

Soni³

2015

J Bioequiv Availab

View full text Add to dashboard Cite

Delivery of the bioactives to the brain is the utmost challenging task to cope with brain diseases. Brain is protected with blood brain barrier, blood-CSF barrier and efflux systems, which controls the entry of body as well as foreign compounds to access the brain cells. Only nutrients, which are essential for normal metabolism, can enter into the brain. In the shadow of this fact new strategies are being investigated to facilitate the entry of administered therapeutic compound into the brain. Active targeting is a evolving approach, which uses ligand and suitable carrier for the site-specific delivery and is being recently achieved by the use of nanocarriers. These nanocarriers are nanosized systems, which act as a cargo for the encapsulated drugs. At the same time, endo-or exogenous ligand can be attached to these nanocarriers to recognize specific receptors on brain capillary endothelium leading to delivery of drug in the vicinity of brain cells. Their potential is under immense investigation to increase the therapeutics outcome in the treatment of brain related problems. This review deals with the recent advances in nanocarriers based novel strategies for effective brain specific delivery.

show abstract

“…SLN are able to carry drugs of different structure and lipophilicity, such as cyclosporine A (Ugazio, Cavalli, & Gasco, 2002), paclitaxel (Cavalli, Caputo, & Gasco, 2000), doxorubicin (Fundaro, Cavalli, Bargoni, Vighetto, & Gasco, 2000), tobramycin (Cavalli et al, 2003), shortchain fatty acids AU9 (Dianzani et al, 2006), peptides (Morel, Cavalli, & Gasco, 1996), antisense oligonucleotides (Brioschi et al, 2008), and melatonin (MT) (Rezzani et al, 2009). Also diagnostic compounds such as iron oxides (Pereira, 2003 AU10 ) have been incorporated into SLN.…”

Section: Solid Lipid Nanoparticles From Warm Microemulsionsmentioning

confidence: 99%

Solid lipid nanoparticles and microemulsions for drug delivery

Gasco¹,

Priano

Zara

2009

Nanoneuroscience and Nanoneuropharmacology

Self Cite

View full text Add to dashboard Cite

Abstract:The chapter examined solid lipid nanoparticles (SLN) and microemulsions, chosen as carriers of drugs, administered in vivo to be transported to the central nervous system. Drugs of different structures and for different therapies have been studied such as doxorubicin SLN stealth and nonstealth administered in rats by intravenous route, apomorphine SLN administered in rats by duodenal route, melatonin SLN administered by transdermal and oral routes in humans, and apomorphine microemulsion administered by transdermal route in Parkinson's patients. The pharmacokinetics of the drug, followed in most studies, put in evidence that the many important pharmacokinetic parameters were notably improved versus the drug alone or in a commercial formulation.

show abstract

Solid Lipid Nanoparticles Carrying Oligonucleotides Inhibit Vascular Endothelial Growth Factor Expression in Rat Glioma Models

Cited by 10 publications

References 0 publications

Transmission Electron Microscopy of Lipid Vesicles for Drug Delivery: Comparison between Positive and Negative Staining

Transmission Electron Microscopy of Lipid Vesicles for Drug Delivery: Comparison between Positive and Negative Staining

Targeted Brain Delivery of Bioactive Molecules Using Nanocarriers

Solid lipid nanoparticles and microemulsions for drug delivery

Contact Info

Product

Resources

About